Nebulized glycyrrhizin/enoxolone drug modulates IL-17A in COVID-19 patients: a randomized clinical trial.
Glycyrrhizin and its derivative Enoxolone show potential as antiviral treatments. This clinical trial focuses on evaluating the safety and effectiveness of a nebulized GA/18β drug for treating COVID-19 patients.
- Zendejas-Hernandez U et al (2024).
- Front Immunol.
- PubMed:
- 38283346